Human T cells genetically modified to express chimeric antigen receptors (CAR) specific to the B cell tumor antigen CD19 can successfully eradicate systemic human CD19 þ tumors in immunocompromised SCID (severe combined immunodeficient)-Beige mice. However, in the clinical setting, CD4 þ CD25 hi T regulatory cells (Treg)
Introduction
T cells may be genetically targeted to tumor antigens through the expression of chimeric antigen receptors (CAR) transduced using retroviral vectors (1) . We have previously demonstrated that human T cells genetically modified to express a CD19-targeted CAR successfully eradicate established systemic human CD19 þ B cell tumor cell lines in immune suppressed SCID (severe combined immunodeficient)-Beige mice (2). However, despite promising preclinical in vivo studies (2-5), results from initial clinical trials utilizing CAR-modified T cells have to date been disappointing (6) (7) (8) .
A potential etiology of treatment failure in the clinical setting may be the suppression of targeted T cells by a hostile tumor microenvironment infiltrated with CD4 þ CD25 hi regulatory T cells (Treg) and myeloid derived suppressor cells, as well as tumor expression of inhibitory ligands (PD-L1) and cytokines (TGF-b and IL-10; refs. [9] [10] [11] . This hostile tumor microenvironment is largely unaddressed in pre-clinical models utilizing immune compromised mice. To address this limitation, we sought to investigate the impact of Tregs, a potent endogenous suppressive element of the immune system, on the antitumor activity of adoptively transferred CAR-modified T cells in a previously established SCID-Beige mouse tumor model. Natural Tregs (nTreg) are CD4 þ T cells derived from the thymus and defined by a CD4 þ CD25 þ CD127 À Foxp3 þ phenotype. nTregs have been found to facilitate suppression of autoimmune T-cell responses and maintenance of peripheral tolerance (12) (13) (14) , represent approximately 5% to 10% of peripheral CD4 þ T cells in both mice and humans (13, 15) , and express high levels of cytotoxic T lymphocyte associated antigen 4 (CTLA-4), glucocorticoid-induced TNFR-related protein, CD39, and CD73 (16) (17) (18) . Patients with cancer, including B cell malignancies, have elevated numbers of Tregs in the peripheral blood and within the tumor microenvironment (19) (20) (21) . Furthermore, in a variety of cancers, increased numbers of Tregs portend a poor prognosis (19, 22) . Although the mechanism of suppression by Tregs appears to be multifactorial (23) , it is clear that the presence of Tregs within the tumor microenvironment could markedly hinder the antitumor efficacy of adoptively transferred tumor-targeted effector T cells (24) .
Many studies have been published implicating Tregs as the cause of failed antitumor immune responses using clinical correlates, Treg depleting strategies (22, 25) , and systemic lymphodepletion (26, 27) . Recently, investigators have developed protocols to readily isolate (28) , stimulate, and expand enriched Treg populations for pre-clinical experimental purposes (29, 30) .
In this report, we investigate the in vivo impact of nTregs on CD19-targeted CAR þ T-cell therapy in a previously established xenotransplant SCID-Beige tumor model of Burkitt lymphoma (2, 3) by recapitulating a clinically relevant tumor microenvironment hostile to effector T-cell function through the infusion of CD19-targeted nTregs. Systemic injection of targeted nTregs into SCID-Beige mice bearing established systemic Raji tumors prior to infusion of CD19-targeted CAR þ effector T cells wholly abolished effector T-cell antitumor benefit while prior treatment with cyclophosphamide effectively reversed in vivo nTreg-mediated suppression of CD19-targeted CAR þ effector T cells. Taken together, our data support the hypothesis that tumor specific nTregs may significantly compromise the antitumor efficacy of CAR-modified tumor-targeted effector T cells in the clinical setting and may, in part, explain the modest clinical outcomes reported in previously published clinical trials utilizing adoptively transferred CAR-modified T cells (6) (7) (8) .
Materials and Methods

Cell lines and T cells
The Raji tumor cell line was cultured in RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated FCS (fetal calf serum), nonessential amino acids, HEPES buffer, pyruvate, and BME (Beta-mercaptoethanol; Life Techonologies). T cells were cultured in RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated FCS supplemented with 20IU IL-2/mL (R&D Systems). PG-13 and gpg29 retroviral producer cell lines were cultured in DMEM (Life Technologies) supplemented with 10% FCS, and NIH-3T3 artificial antigenpresenting cells (AAPC), were cultured in DMEM supplemented with 10% heat-inactivated donor calf serum. All media were supplemented with 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin (Life Technologies).
Isolation of CD4
þ CD25 À effector T cells and CD4
Peripheral blood from healthy donors, obtained under institutional review board-approved protocol 95-054, was fractionated in BD Vacutainer CPT tubes (BD Medical), to isolate peripheral blood mononuclear cells (PBMC). CD4 þ
CD25
À responder T cells and CD4 þ CD25 þ nTregs were isolated from PBMCs using the CD4 þ CD25 þ Regulatory TCell Isolation Kit (Dynal brand; Invitrogen).
Retroviral genetic modification of T cells
Generation of retroviral producer PG-13 cell lines and gene transfer into effector T cells have been previously described (3, 31) . For nTreg retroviral gene transfer, isolated nTregs were activated with Dynal CD3/CD28 Human Treg Expander magnetic beads (Invitrogen), cultured in RPMI media supplemented with IL-2 500IU and Rapamycin 100ng/mL (Sigma) for 48 hours (30, 32) , and similarly transduced. 
Expansion of CAR
Cytokine detection assays
Cytokine levels in tissue culture supernatant as well as serum were assessed using the multiplex Human Cytokine Detection System (Millipore Corp.) in conjunction with the Luminex IS100 system and IS 2.2 software (Luminex Corp.). 
In vitro
Bioluminescent imaging
For in vivo imaging of Raji tumor cells we utilized Raji tumor cells modified to express GFP-FFLuc (Clontech Laboratories). Imaging of nTregs was performed using nTregs modified with the previously described 19z1 IRES extGLuc bicistronic retroviral vector (34) . Tumor and T cells were imaged using the Xenogen IVIS Imaging System (Xenogen; ref. 34 ).
Immunohistochemistry staining
Mouse bone marrow samples were fixed in 10% buffered formalin phosphate (Fisher Scientific). All tissues were processed by routine methods and embedded in paraffin wax. Five-micrometer sections were stained with H&E (Poly Scientific). Human T cells in the paraffin-embedded mouse tissues were detected using rabbit polyclonal sera specific to human CD3 (DakoCytomation).
Flow cytometry
We performed FACS with a FACScan cytometer with FlowJo software (Tree Star), using PE-labeled CAR-specific monoclonal antibody (12D11, MSKCC monoclonal antibody core facility), FITC-labeled human CD4 specific antibody (S3.5, Caltag), CD8 specific antibody (3B5, Caltag), CD62L specific antibody (DREG 56, BD Pharmingen), PE-labeled human CD25 specific antibody (CD25.3G10, Caltag), and APC-labeled human CD19 specific antibody (SJ25-C, Caltag). Foxp3 expression was assessed using the Human Regulatory T cell Staining Kit (eBioscience).
Statistical analysis
Statistical analysis utilizing the GraphPad Prism software (GraphPad Software) was done using log-rank analyses for survival and the Student's t-test and Wilcoxon rank sum test for line and bar graph comparisons.
Results
nTregs are efficiently modified to express CARs by retroviral transduction
To assess whether human nTregs can be genetically manipulated despite their anergic nature and difficulty to maintain in culture (30, 35) , we isolated nTregs using immunomagnetic sorting for the CD4 þ CD25 hi population from PBMCs consistently achieving CD4 þ T-cell populations that were more than 95% CD25 hi , 70% to 90% Foxp3 þ ( Fig. 1A and B), CD62L hi and CD127 À (data not shown). CD3/CD28 bead activated nTregs were subsequently transduced with CD19-targeted CARs using retroviral supernatants, routinely resulting in more than 60% gene transfer ( Fig 1C) . In order to assess whether CAR-modified nTregs efficiently traffic to Raji tumors in SCID-Beige mice, we employed dual bioluminescent imaging (BLI) enabling simultaneous imaging of both tumor cells and T cells within the same animal (34) . SCID-Beige mice previously injected subcutaneously with Raji (GFP-FFLuc) tumor cells underwent BLI to verify detectable tumor (Fig. 3A) Cell number x 10 6 % CAR+ T cells Absolute CAR + cell number at a nTreg to effector T-cell ratio as low as 1:8, but found recovery of effector T-cell antitumor efficacy at a 1:16 nTreg to effector T-cell ratio (Fig. 4B) . Similar results were obtained when this experiment was conducted using 19-28z þ nTregs (data not shown).
Optimal suppression of 19-28z þ effector T cells requires nTreg activation within the tumor microenvironment We next generated a CD19-targeted CAR lacking the z chain signaling domain termed 19(del) (Fig 5A) . 19(del) þ nTregs failed to expand on 3T3(CD19/CD80) AAPCs verifying the lack of T-cell activating signaling by the z chain-deleted 19(del) CAR (Fig 5B) . However, despite loss of CAR signaling, 19(del) þ nTregs retained the capacity to traffic to CD19 þ Raji tumors in vivo (Fig 5C) and the ability to potently suppress both naïve T-cell proliferation (Fig. 5D ) and 19-28z effector T-cell cytotoxicity in vitro (data not shown).
In order to assess the in vivo inhibitory capacity of 19(del) Fig. 5F and G) . This finding is consistent with sequestration of IL-2 by nTregs, a previously described mechanism of nTreg-mediated T-cell suppression (35, 36) , and inhibition of effector T-cell activation as assessed by IFNg levels. These findings were independent of nTreg activation status, and may explain, in part, the observed partial inhibition mediated by 19(del) þ nTregs.
Cyclophosphamide lymphodepletion eradicates 19z1
þ nTregs and restores antitumor efficacy of 19-28z þ effector T cells Lymphodepleting preconditioning regimens can enhance the antitumor efficacy of adoptively transferred cytotoxic T cells which may be mediated in part through the eradication of Tregs in the host (26, 27) . In particular, cyclophosphamide chemotherapy has been shown to effectively eliminate Tregs (37) (38) (39) . To this end, we next investigated whether cyclophosphamide therapy (100 mg/kg) following infusion of 19z1 T-cell-treated control cohort (Fig. 6A) . FACS analyses to assess the 19z1 þ nTreg to 19-28z þ effector T-cell ratios in the bone marrow of cyclophosphamide treated mice at 24 hours post 19-28z þ effector T-cell infusion demonstrated a 0.14 nTreg to effector T-cell ratio, in contrast to a 0.9 nTreg to effector T-cell ratio seen in nonlymphodepleted mice (Fig. 6B) . These data verify cyclophosphamide depletion of endogenous nTregs.
Discussion
The generation of tumor-targeted T cells for adoptive therapy may be insufficient to achieve significant antitumor responses in the clinical setting. Specifically, the tumor itself may foster an environment capable of impairing targeted effector T-cell function. Specifically, Tregs, which are relevant in both the clinic and in immune-competent animal models of disease (40, 41) , are absent in the xenograft tumor models previously used to study modified human T cells in vivo.
Herein we report that isolated human nTregs from healthy donors may be efficiently transduced to express CARs and subsequently expanded in vitro. While other groups have examined the effects of induced Tregs (iTreg) toward similar ends (42), we opted to isolate and expand nTregs due to concerns regarding the stability of FOXP3 expression in iTregs (43) . The resulting tumor-targeted nTregs successfully traffic to tumor in SCID-Beige mice recapitulating a hostile tumor microenvironment seen in the clinical setting. nTreg infiltrated tumors were markedly resistant to eradication by CARmodified effector T cells even at low (1:8) nTreg to effector T-cell ratios, while tumor resistance to effector T-cell eradication was no longer apparent at a ratio of 1:16, consistent with a dose dependent nTreg-mediated suppression. This dose dependent nature of inhibition, evidence of persistence of tumor-targeted nTregs within the tumors, and the inability of nontumor-targeted control Pz1 þ nTregs to inhibit 19-28z þ effector T cells even at a 1:1 ratio, all support the notion that the suppression of tumor-targeted effector T cells is specifically dependent upon the presence of these nTregs within the tumor microenvironment. While our in vitro data suggest that 19z1 þ Tregs are capable of inhibiting both CAR-mediated cytotoxicity and proliferation, which of these factors predominates in vivo in this tumor model is currently unclear. However, our prior studies suggest that proliferation or persistence does not play a dominant role in this tumor model, as multiple infusions of 19-28z þ T cells are needed to achieve optimal antitumor efficacy in a pre B cell ALL tumor model (3) . These data are consistent with limited in vivo persistence and proliferation of the CARmodified cells in SCID-Beige mice favoring inhibited effector T-cell cytotoxicity by colocalized nTregs as the primary mechanism of suppression observed in our studies. The mechanism of in vivo nTreg suppression in our model further appears to be dependent, in part, on the activation status of nTregs at the tumor site since nTregs modified to express the 19(del) CAR retained a statistically significant ability to suppress in vivo effector T-cell function when T-cell infusion, prior infusion with either 19z1 þ or 19(del) þ nTregs significantly reduced serum levels of (F) IL-2 (P < 0.005), and (G) IFNg (P < 0.05), when compared to mice treated with 19-28z þ effector T cells alone. Figure 5F and G represents the combined data from 2 independent experiments with cohorts of 3 mice in each experiment.
Our data are consistent with the notion that tumor infiltrating Tregs may represent a significant obstacle to the successful application of this adoptive cell therapy. One relatively direct method of overcoming this obstacle would be to eliminate Tregs prior to CAR-modified T-cell infusion. While several therapeutic options exist for this purpose, including anti-CD25 antibodies and immunotoxins (45), we chose cyclophosphamide due to its established ability to eliminate Tregs in the context of an antitumor response (46, 47) as well as the applicability of this approach to ongoing Phase I clinical trials at our center using autologous 19-28z modified T cells to treat patients with relapsed or refractory B cell malignances. In our studies, prior lymphodepletion with cyclophosphamide before adoptive cell therapy of SCID-Beige mice bearing systemic established Raji tumors infiltrated with 19z1 þ nTregs abrogated the suppression of subsequently infused 19-28z þ effector T cells by significantly lowering the nTreg to effector T-cell ratios from 0.90 to 0.14 within the tumor microenvironment (Fig. 6B) . These data are furthermore consistent with our observed in vivo dose dependent nTreg-mediated suppression of effector T cells (Fig. 4B ).
In conclusion, these data validate concerns that a hostile tumor microenvironment may markedly compromise CARmodified effector T-cell antitumor efficacy in the clinical setting. Further our data support the incorporation of lymphodepleting chemotherapy prior to infusion of CAR-modified tumor-targeted T cells in the modification of ongoing clinical trials and the design of future clinical trials. Finally, our data support the potential of CAR-modified nTregs as a novel approach for the treatment of autoimmune diseases. Long-term survival comparable to no-nTreg controls was observed in mice injected with 19z1 þ nTregs followed by cyclophosphamide therapy and 19-28z þ effector T-cell infusion which was significantly superior to similarly treated mice without prior lymphodepletion (P < 0.0001). Data represent combined results from 2 independent experiments. B, Foxp3 þ nTreg to effector cell ratios were assessed in tumor-involved tissues (bone marrow) by FACS at 24 hours following 19-28z þ effector T-cell infusion. Prior cyclophosphamide therapy significantly altered the nTreg to effector T-cell ratios in favor of the 19-28z þ effector T cells (0.14 with vs. 0.9 without lymphodepletion, P < 0.005). Data represent the average from 2 independent experiments each with cohorts of 3 mice per treatment group.
